Outcomes at 5 years according to phase of therapy in CCG-2961
| . | . | Regimen A: IdaDCTER/DCTER . | Regimen B: Famp/AC/Ida . | P . | Donor . | No donor . | P . | IL-2 . | No IL-2 . | P . |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 4 | 4 |
| N | 901 | 367 | 371 | — | 170 | 463 | — | 144 | 145 | — |
| Outcome | ||||||||||
| CR/PR | 88% | 88% | 89% | .895 | — | — | — | — | — | — |
| Die | 6% | 4% | 8% | .060 | 8% | 3% | .007 | 0% | 3% | .122 |
| Fail/relapse | 6% | 7% | 3% | .018 | 2% | 4% | .349 | 5% | 3% | .377 |
| Withdraw | 7% | 8% | 10% | — | — | — | — | — | — | — |
| Inevaluable | 2% | 3% | 3% | — | — | — | — | — | — | — |
| OS±2 SE | 52 ± 4% | 59 ± 5% | 56 ± 6% | .612 | 67 ± 8% | 62 ± 5% | .425 | 70 ± 8% | 73 ± 8% | .727 |
| EFS±2 SE | 42 ± 3% | 46 ± 5% | 49 ± 5% | .361 | — | — | — | — | — | — |
| DFS±2 SE | — | — | — | — | 60 ± 8% | 50 ± 5% | .021 | 51 ± 9% | 58 ± 8% | .489 |
| . | . | Regimen A: IdaDCTER/DCTER . | Regimen B: Famp/AC/Ida . | P . | Donor . | No donor . | P . | IL-2 . | No IL-2 . | P . |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 4 | 4 |
| N | 901 | 367 | 371 | — | 170 | 463 | — | 144 | 145 | — |
| Outcome | ||||||||||
| CR/PR | 88% | 88% | 89% | .895 | — | — | — | — | — | — |
| Die | 6% | 4% | 8% | .060 | 8% | 3% | .007 | 0% | 3% | .122 |
| Fail/relapse | 6% | 7% | 3% | .018 | 2% | 4% | .349 | 5% | 3% | .377 |
| Withdraw | 7% | 8% | 10% | — | — | — | — | — | — | — |
| Inevaluable | 2% | 3% | 3% | — | — | — | — | — | — | — |
| OS±2 SE | 52 ± 4% | 59 ± 5% | 56 ± 6% | .612 | 67 ± 8% | 62 ± 5% | .425 | 70 ± 8% | 73 ± 8% | .727 |
| EFS±2 SE | 42 ± 3% | 46 ± 5% | 49 ± 5% | .361 | — | — | — | — | — | — |
| DFS±2 SE | — | — | — | — | 60 ± 8% | 50 ± 5% | .021 | 51 ± 9% | 58 ± 8% | .489 |
— indicates not applicable.